Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-demecolcine | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Demecolcine results in increased expression of H2BC5 mRNA | CTD | PMID:23649840 | (S)-nicotine | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Nicotine results in increased expression of H2BC5 protein | CTD | PMID:35929799 | 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | o and p'-DDT results in decreased expression of H2BC5 mRNA | CTD | PMID:19371625 | 17beta-estradiol | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Estradiol results in decreased expression of H2BC5 mRNA | CTD | PMID:23019147 | 17beta-estradiol | affects expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Estradiol affects the expression of H2BC5 mRNA | CTD | PMID:22574217 | 17beta-estradiol | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [Progesterone co-treated with Estradiol] results in increased expression of H2BC5 mRNA | CTD | PMID:17404688 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of H2BC5 mRNA | CTD | PMID:17101203 more ... | 2-hydroxypropanoic acid | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Lactic Acid results in decreased expression of H2BC5 mRNA | CTD | PMID:30851411 | 2-methylcholine | affects expression | ISO | H2BC5 (Homo sapiens) | 6480464 | beta-methylcholine affects the expression of H2BC5 mRNA | CTD | PMID:21179406 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of H2BC5 mRNA | CTD | PMID:28628672 | 4-\{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino\}benzoic acid | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Am 580 results in decreased expression of H2BC5 mRNA | CTD | PMID:16982809 | 5-aza-2'-deoxycytidine | affects expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Decitabine affects the expression of H2BC5 mRNA | CTD | PMID:23300844 | 6-propyl-2-thiouracil | decreases expression | EXP | | 6480464 | Propylthiouracil results in decreased expression of HIST1H2BD mRNA | CTD | PMID:24780913 and PMID:25825206 | 6-propyl-2-thiouracil | increases expression | EXP | | 6480464 | Propylthiouracil results in increased expression of HIST1H2BD mRNA | CTD | PMID:30047161 | acetamide | increases expression | EXP | | 6480464 | acetamide results in increased expression of HIST1H2BD mRNA | CTD | PMID:31881176 | acrylamide | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Acrylamide results in increased expression of H2BC5 mRNA | CTD | PMID:32763439 | aflatoxin B1 | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Aflatoxin B1 results in increased expression of H2BC5 mRNA | CTD | PMID:27153756 | aflatoxin B1 | decreases methylation | ISO | H2BC5 (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased methylation of H2BC5 gene | CTD | PMID:27153756 | all-trans-retinoic acid | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Tretinoin results in decreased expression of H2BC5 mRNA | CTD | PMID:21934132 | amitrole | increases expression | EXP | | 6480464 | Amitrole results in increased expression of HIST1H2BD mRNA | CTD | PMID:30047161 | antimycin A | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Antimycin A results in increased expression of H2BC5 mRNA | CTD | PMID:33512557 | aristolochic acid A | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | aristolochic acid I results in increased expression of H2BC5 mRNA and aristolochic acid I results in increased expression of HIST1H2BD mRNA | CTD | PMID:33212167 | arsenous acid | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [Arsenic Trioxide co-treated with Ascorbic Acid] results in decreased expression of H2BC5 mRNA | CTD | PMID:25555879 | arsenous acid | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Arsenic Trioxide results in decreased expression of H2BC5 mRNA and Arsenic Trioxide results in decreased expression of HIST1H2BD mRNA | CTD | PMID:25555879 and PMID:26705709 | azathioprine | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Azathioprine results in increased expression of H2BC5 mRNA | CTD | PMID:22623647 | belinostat | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | belinostat results in decreased expression of H2BC5 mRNA | CTD | PMID:26272509 | belinostat | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA | CTD | PMID:27188386 | benzo[a]pyrene | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased expression of H2BC5 mRNA | CTD | PMID:20064835 more ... | benzo[a]pyrene diol epoxide I | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | 7 more ... | CTD | PMID:20382639 | berberine | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Berberine results in decreased expression of H2BC5 mRNA | CTD | PMID:27311644 | bis(2-chloroethyl) sulfide | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Mustard Gas results in increased expression of H2BC5 mRNA | CTD | PMID:25102026 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of HIST1H2BD mRNA | CTD | PMID:25181051 more ... | bisphenol A | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of H2BC5 mRNA | CTD | PMID:28628672 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of H2BC15 mRNA and bisphenol A results in decreased expression of HIST1H2BD mRNA | CTD | PMID:25181051 | bisphenol A | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | bisphenol A results in decreased expression of H2BC5 mRNA | CTD | PMID:19371625 and PMID:29275510 | bisphenol A | increases methylation | EXP | | 6480464 | bisphenol A results in increased methylation of HIST1H2BD gene | CTD | PMID:28505145 | C60 fullerene | increases expression | EXP | | 6480464 | fullerene C60 results in increased expression of H2BC15 mRNA | CTD | PMID:19167457 | calcitriol | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Calcitriol results in increased expression of H2BC5 mRNA | CTD | PMID:21592394 | calcitriol | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of H2BC5 mRNA | CTD | PMID:21592394 | cisplatin | affects expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Cisplatin affects the expression of H2BC5 mRNA | CTD | PMID:23300844 | clotrimazole | increases expression | EXP | | 6480464 | Clotrimazole results in increased expression of HIST1H2BD mRNA | CTD | PMID:30047161 | copper atom | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of H2BC5 mRNA | CTD | PMID:20971185 | copper(0) | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of H2BC5 mRNA | CTD | PMID:20971185 | copper(II) sulfate | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Copper Sulfate results in increased expression of H2BC5 mRNA | CTD | PMID:19549813 | coumestrol | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Coumestrol results in decreased expression of H2BC5 mRNA | CTD | PMID:19167446 | coumestrol | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [Coumestrol co-treated with 2 more ... | CTD | PMID:19167446 | crocidolite asbestos | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Asbestos and Crocidolite results in increased expression of H2BC5 mRNA | CTD | PMID:25351596 | curcumin | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Curcumin results in increased expression of H2BC5 mRNA | CTD | PMID:17999991 | cyclosporin A | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Cyclosporine results in decreased expression of H2BC5 mRNA | CTD | PMID:20106945 and PMID:27989131 | decabromodiphenyl ether | affects expression | ISO | H2BC5 (Homo sapiens) | 6480464 | decabromobiphenyl ether affects the expression of H2BC5 mRNA | CTD | PMID:24834073 | deguelin | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | deguelin results in increased expression of H2BC5 mRNA | CTD | PMID:33512557 | deoxynivalenol | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | deoxynivalenol results in increased expression of H2BC5 mRNA | CTD | PMID:31863870 | dexamethasone | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of H2BC5 mRNA | CTD | PMID:28628672 | diarsenic trioxide | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Arsenic Trioxide results in decreased expression of H2BC5 mRNA and Arsenic Trioxide results in decreased expression of HIST1H2BD mRNA | CTD | PMID:25555879 and PMID:26705709 | diarsenic trioxide | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [Arsenic Trioxide co-treated with Ascorbic Acid] results in decreased expression of H2BC5 mRNA | CTD | PMID:25555879 | dorsomorphin | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Doxorubicin results in decreased expression of H2BC5 mRNA | CTD | PMID:29803840 | Enterolactone | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [Coumestrol co-treated with 2 and 3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2BC5 mRNA | CTD | PMID:19167446 | entinostat | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | entinostat results in decreased expression of H2BC5 mRNA | CTD | PMID:26272509 | entinostat | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA | CTD | PMID:27188386 | fenpyroximate | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | fenpyroximate results in increased expression of H2BC5 mRNA | CTD | PMID:33512557 | flutamide | increases expression | EXP | | 6480464 | Flutamide results in increased expression of H2BC15 mRNA | CTD | PMID:24793618 | formaldehyde | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Formaldehyde results in increased expression of H2BC5 mRNA | CTD | PMID:23649840 | genistein | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Genistein results in decreased expression of H2BC5 mRNA | CTD | PMID:19371625 | hydrogen peroxide | affects expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Hydrogen Peroxide affects the expression of H2BC5 mRNA | CTD | PMID:21179406 | indometacin | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of H2BC5 mRNA | CTD | PMID:28628672 | iron dichloride | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | ferrous chloride results in increased expression of H2BC5 mRNA | CTD | PMID:35984750 | isotretinoin | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Isotretinoin results in decreased expression of H2BC5 mRNA | CTD | PMID:20436886 | L-ascorbic acid | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [Arsenic Trioxide co-treated with Ascorbic Acid] results in decreased expression of H2BC5 mRNA | CTD | PMID:25555879 | Licochalcone B | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | licochalcone B results in increased expression of H2BC5 mRNA | CTD | PMID:33647349 | mercury dibromide | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | mercuric bromide results in decreased expression of H2BC5 mRNA | CTD | PMID:26272509 | mercury dibromide | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA | CTD | PMID:27188386 | methimazole | increases expression | EXP | | 6480464 | Methimazole results in increased expression of HIST1H2BD mRNA | CTD | PMID:30047161 | methyl methanesulfonate | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Methyl Methanesulfonate results in increased expression of H2BC5 mRNA | CTD | PMID:23649840 | methylisothiazolinone | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | 2-methyl-4-isothiazolin-3-one results in increased expression of H2BC5 mRNA | CTD | PMID:31629900 | methylparaben | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | methylparaben results in increased expression of H2BC5 mRNA | CTD | PMID:31745603 | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | N more ... | CTD | PMID:19013360 | nicotine | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Nicotine results in increased expression of H2BC5 protein | CTD | PMID:35929799 | p-chloromercuribenzoic acid | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA | CTD | PMID:27188386 | p-chloromercuribenzoic acid | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | p-Chloromercuribenzoic Acid results in decreased expression of H2BC5 mRNA | CTD | PMID:26272509 | paracetamol | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Acetaminophen results in increased expression of H2BC5 mRNA | CTD | PMID:21420995 | perfluorooctanoic acid | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | perfluorooctanoic acid results in increased expression of H2BC5 mRNA | CTD | PMID:36326898 | progesterone | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [Progesterone co-treated with Estradiol] results in increased expression of H2BC5 mRNA | CTD | PMID:17404688 | propionic acid | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | propionic acid results in decreased expression of H2BC5 mRNA | CTD | PMID:31526819 | pyrimidifen | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | pyrimidifen results in increased expression of H2BC5 mRNA | CTD | PMID:33512557 | quercetin | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Quercetin results in increased expression of H2BC5 mRNA | CTD | PMID:21632981 | rac-lactic acid | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Lactic Acid results in decreased expression of H2BC5 mRNA | CTD | PMID:30851411 | resveratrol | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Resveratrol results in decreased expression of H2BC5 mRNA | CTD | PMID:19371625 | resveratrol | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [Coumestrol co-treated with Resveratrol] results in decreased expression of H2BC5 mRNA and [Plant Extracts co-treated with Resveratrol] results in decreased expression of H2BC5 mRNA | CTD | PMID:19167446 and PMID:23557933 | rotenone | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Rotenone results in increased expression of H2BC5 mRNA | CTD | PMID:33512557 | SB 431542 | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | silicon dioxide | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Silicon Dioxide analog results in increased expression of H2BC5 mRNA and Silicon Dioxide results in increased expression of H2BC5 mRNA | CTD | PMID:23806026 and PMID:25351596 | sodium arsenite | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | sodium arsenite results in decreased expression of H2BC5 mRNA | CTD | PMID:24516582 | sulfadimethoxine | increases expression | EXP | | 6480464 | Sulfadimethoxine results in increased expression of HIST1H2BD mRNA | CTD | PMID:30047161 | sunitinib | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Sunitinib results in decreased expression of H2BC5 mRNA | CTD | PMID:31533062 | T-2 toxin | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | T-2 Toxin results in increased expression of H2BC5 mRNA | CTD | PMID:31863870 | tebufenpyrad | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | 4-chloro-N-((4-(1 and 1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide results in increased expression of H2BC5 mRNA | CTD | PMID:33512557 | tert-butyl hydroperoxide | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | tert-Butylhydroperoxide results in increased expression of H2BC5 mRNA | CTD | PMID:15336504 | testosterone | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Testosterone results in increased expression of H2BC5 mRNA | CTD | PMID:21592394 | testosterone | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of H2BC5 mRNA | CTD | PMID:21592394 | thifluzamide | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | thifluzamide results in increased expression of H2BC5 mRNA | CTD | PMID:33512557 | triadimefon | increases expression | EXP | | 6480464 | triadimefon results in increased expression of HIST1H2BD mRNA | CTD | PMID:30047161 | trichostatin A | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of H2BC5 mRNA | CTD | PMID:24935251 and PMID:26272509 | trichostatin A | multiple interactions | ISO | H2BC5 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA | CTD | PMID:27188386 | troglitazone | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Troglitazone results in increased expression of H2BC5 mRNA | CTD | PMID:19140230 | urethane | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Urethane results in increased expression of H2BC5 mRNA | CTD | PMID:28818685 | valproic acid | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of H2BC5 mRNA | CTD | PMID:28001369 | valproic acid | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of H2BC5 mRNA | CTD | PMID:24383497 more ... | valproic acid | affects expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Valproic Acid affects the expression of H2BC5 mRNA | CTD | PMID:25979313 | vincristine | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Vincristine results in increased expression of H2BC5 mRNA | CTD | PMID:23649840 | zearalenone | decreases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Zearalenone results in decreased expression of H2BC5 mRNA | CTD | PMID:19371625 | zoledronic acid | increases expression | ISO | H2BC5 (Homo sapiens) | 6480464 | Zoledronic Acid results in increased expression of H2BC5 mRNA | CTD | PMID:24714768 | |